Clinical Trial Update: Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, and preliminary efficacy of LNA043 in autologous chondrocyte implantation for knee cartilage lesion; study termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Knee Cartilage Lesion

Drugs mentioned

• LNA043

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Knee Cartilage Lesion | Phase 2 | Status: TERMINATED | Results posted: 2020-04-17